OT mobile menu



Slide Show: Trends in Targeted Therapies and Immunotherapies

Check out our slide show on current trends in targeted therapies and immunotherapies


Image © Anita Ponne/ Shutterstock.com.
Image © Anita Ponne/ Shutterstock.com.
Image © Anita Ponne/ Shutterstock.com.
Image © Blamb / Shutterstock.com.
Image © Blamb / Shutterstock.com.
Image © Blamb / Shutterstock.com.
Nivolumab showed greater overall survival in patients with metastatic squamous NSCLC, - See more at: http://www.oncotherapynetwork.com/asco-2015/nivolumab-improves-response-...

Recent Content

The US Food and Drug Administration (FDA) on September 1, 2015, accepted for Priority Review the Biologics License Application for elotuzumab (Empliciti) for the treatment of multiple myeloma as combination therapy in patients who have received one or more prior therapies.

The US Food and Drug Administration (FDA) have granted a priority review for Merck’s anti-PD-1 agent pembrolizumab (Keytruda) as a first-line treatment of advanced melanoma, the company announced.

New computer programs have been developed that accurately predict how a person reacts to different cancer therapies based on their genetic makeup.

Highly druggable ion channels, which are common therapeutic targets for heart disease and neurological conditions, may represent useful targets in cancer treatment as well, according to researchers from the University of California at San Francisco.

A new three-pronged approach may help better identify patients who have Lynch syndrome, an inherited cancer susceptibility syndrome that predisposes individuals to various cancers, according to researchers at Baylor College of Medicine.

Patients with renal cell carcinoma (RCC) who have not responded to prior therapy may soon have a new treatment option.

A recent study shows that the investigational drug EP-100--a synthetic cytolytic peptide conjugated to a luteinizing hormone releasing hormone (LHRH) -- may be a treatment option for taxane-resistant ovarian cancer.

By clicking Accept, you agree to become a member of the UBM Medica Community.